Webinar
Going Non-Viral: How Cell Therapy Manufacturing is Moving Away From Viral Vectors

Are you interested in editing cells using a CRISPR-based non-viral vector capable of achieving knock-in rates of 70–90%? Don’t miss this webinar discussing this approach and the specific strategies to improve manufacturing timelines and costs.

Past and present, viral vectors have been the gold standard for cell therapy manufacturing, but novel manufacturing modalities are now emerging in the market.

Non-viral CRISPR methods with enrichment and selection systems have improved manufacturing costs, yields, and timelines.

Learn how these specific methods generate 70–90% knock-in rates in clinically relevant cells.

Watch Dr. John Zuris from Editas Medicine and Dr. Hyatt Blake-Want, a post-doctoral scholar at Stanford and hematology-oncology resident at Cologne University Hospital, as we discuss their novel manufacturing approaches.

In this webinar, we discussed:

• Novel CRISPR-based methods to generate 70-90% knock-in rates in clinically relevant cells.
• How these non-viral methods can improve manufacturing costs, yields, and timelines
• Paradigm shifts from viral vector manufacturing of CAR-T cells to non-viral methodologies.
• The future of CAR-T cell therapies in the market
• An interactive Q&A

Fill out the form to get access now!